# Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Canonical URL: https://biopharmsignal.com/news/TIL/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-tumors
Ticker: TIL
Company: Instil Bio
Source: Instil Bio
Published: 2025-07-02 10:00 EST
Original Source URL: https://ir.instilbio.com
## Summary

US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc.

## Article Body
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc.
## Recent Company News
- 2026-05-15 11:00 EST — [Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-03-27 11:00 EST — [Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-01-06 12:00 EST — [Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco](https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco) — Source: Instil Bio
- 2025-11-13 12:00 EST — [Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2025-09-10 11:00 EST — [Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)](https://biopharmsignal.com/news/TIL/instil-bio-announces-immuneonco-s-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc) — Source: Instil Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)